/MIRM
MIRM Stock - Mirum Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$77.74+10.61%
+$7.46 (+10.61%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+29.7%upside
Target: $100.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MIRM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$76.96 – $78.52
TARGET (TP)$100.82
STOP LOSS$71.52
RISK/REWARD1:3.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.42
52W High$79.95
52W Low$36.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $336.89M | $186.37M | $77.06M | $19.14M | N/A |
| Gross Profit | $255.25M | $139.34M | $64.69M | $17.23M | $-623,000 |
| Gross Margin | 75.8% | 74.8% | 83.9% | 90.1% | N/A |
| Operating Income | $-87,606,000 | $-109,154,000 | $-131,220,000 | $-173,413,000 | $-104,296,000 |
| Net Income | $-87,942,000 | $-163,415,000 | $-135,665,000 | $-83,988,000 | $-103,270,000 |
| Net Margin | -26.1% | -87.7% | -176.0% | -438.9% | N/A |
| EPS | $-1.85 | $-4.00 | $-4.01 | $-2.77 | $-4.09 |
Company Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$62
Average Target
↓ 20.5% Downside
Now
$37
Low
$62
Average
$95
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 24th 2025 | TD Cowen | Initiation | Buy | $95 |
| August 11th 2025 | Stifel | Resumed | Buy | $89 |
| May 19th 2025 | H.C. Wainwright | Resumed | Buy | $73 |
| April 17th 2024 | Stifel | Initiation | Buy | $48 |
| December 18th 2023 | H.C. Wainwright | Reiterated | Buy | $58← $60 |
| November 20th 2023 | JP Morgan | Resumed | Overweight | $37 |
| November 13th 2023 | Morgan Stanley | Initiation | Overweight | $60 |
| October 24th 2023 | Cantor Fitzgerald | Initiation | Overweight | $50 |
| October 17th 2023 | Evercore ISI | Resumed | Outperform | $62 |
| September 20th 2023 | JMP Securities | Initiation | Mkt Outperform | $70 |
| September 1st 2022 | Citigroup | Initiation | Buy | $38 |
Earnings History & Surprises
MIRMBeat Rate
56%
Last 18 quarters
Avg Surprise
-11.1%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$0.05
Q4 2025
EPS Surprise History
Q1 24
-94.1%
$-0.66vs$-0.34
Q2 24
-35.0%
$-0.54vs$-0.40
Q3 24
-8.3%
$-0.52vs$-0.48
Q4 24
+33.3%
$-0.30vs$-0.45
Q1 25
-81.5%
$-0.49vs$-0.27
Q2 25
+23.1%
$-0.30vs$-0.39
Q3 25
+61.3%
$-0.12vs$-0.31
Q4 25
+150.0%
$0.05vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.10 | $0.05 | +150.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.31 | $-0.12 | +61.3% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.39 | $-0.30 | +23.1% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.27 | $-0.49 | -81.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.45 | $-0.30 | +33.3% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.48 | $-0.52 | -8.3% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.40 | $-0.54 | -35.0% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.34 | $-0.66 | -94.1% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.64 | $-0.57 | +10.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.81 | $-0.92 | -13.6% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.96 | $-0.80 | +16.7% | ✓ BEAT |
Q1 2023 | Mar 8, 2023 | $-0.98 | $-0.99 | -1.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-1.05 | $-1.02 | +2.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-1.05 | $-0.84 | +20.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.39 | $-1.17 | +15.8% | ✓ BEAT |
Q1 2022 | Mar 9, 2022 | $-0.61 | $-0.92 | -50.8% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-1.63 | $-1.55 | +4.9% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.41 | $-1.45 | -253.7% | ✗ MISS |
Latest News
Mirum Pharmaceuticals Files Patent Infringement Lawsuits To Block FDA Approval Of Generic Livmarli Following ANDA Filings By Sandoz, Annora, Zydus, Zenara
📉 NegativeBenzinga•Dec 19, 2025, 09:27 PM•Also:
Mirum Pharmaceuticals shares are trading higher after the company announced a $68.5 million private placement agreement with TCGX. Also, Citizens raised its price target on the stock from $95 to $140.
📈 PositiveBenzinga•Dec 19, 2025, 04:02 PM
Mirum Pharma Enters $68.5M Private Placement Agreement With TCGX For 1M Shares At $68.48 Each
📈 PositiveBenzinga•Dec 19, 2025, 01:33 PM
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $140
📈 PositiveBenzinga•Dec 19, 2025, 01:31 PM
Mirum Pharmaceuticals shares are trading higher after Stifel maintained the stock with a Buy rating and raised the price target from $92 to $98.
📈 PositiveBenzinga•Dec 16, 2025, 05:46 PM•Also:
Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $98
📈 PositiveBenzinga•Dec 16, 2025, 05:27 PM•Also:
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $95
📈 PositiveBenzinga•Dec 9, 2025, 05:17 PM
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $88
📈 PositiveBenzinga•Dec 9, 2025, 04:46 PM
Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $94
📈 PositiveBenzinga•Dec 9, 2025, 03:29 PM
Mirum Pharmaceuticals Enters Definitive Agreement To Acquire Bluejay Therapeutics For $250M In Cash And $370M In Mirum Common Stock Plus Tiered Sales-Based Milestones Up To $200M
📈 PositiveBenzinga•Dec 8, 2025, 01:01 PM
Mirum Pharmaceuticals Enrolls First Participant Enrollment In Bloom Phase 2 Study Evaluating MRM-3379 For Fragile X Syndrome
➖ NeutralBenzinga•Dec 1, 2025, 01:15 PM
Mirum Pharmaceuticals Receives Paragraph IV Notice From Sandoz On Livmarli; Sandoz Alleges Five Livmarli Patents Invalid Or Unenforceable; To File Patent Infringement Suit Against Sandoz
📉 NegativeBenzinga•Nov 17, 2025, 09:57 PM•Also:
Mirum Pharma To Share Multiple Presentations Featuring Data From LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting 2025
📈 PositiveBenzinga•Nov 7, 2025, 01:12 PM
Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $95
📈 PositiveBenzinga•Nov 5, 2025, 04:08 PM
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $95
📈 PositiveBenzinga•Nov 5, 2025, 01:01 PM
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $81
📈 PositiveBenzinga•Nov 5, 2025, 11:32 AM
Mirum Pharmaceuticals Raises FY2025 Sales Guidance from $490.000M-$510.000M to $500.000M-$510.000M vs $505.800M Est
📈 PositiveBenzinga•Nov 4, 2025, 09:03 PM
Mirum Pharmaceuticals Q3 EPS $0.05 Beats $(0.14) Estimate, Sales $133.010M Beat $130.074M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:02 PM
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $81
📈 PositiveBenzinga•Oct 16, 2025, 06:00 PM
TD Cowen Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $95
📈 PositiveBenzinga•Sep 24, 2025, 04:01 PM
Frequently Asked Questions about MIRM
What is MIRM's current stock price?
Mirum Pharmaceuticals, Inc. (MIRM) is currently trading at $77.74 per share. The stock has moved +10.61% today.
What is the analyst price target for MIRM?
The average analyst price target for MIRM is $100.82, based on 1 analyst.
What sector is Mirum Pharmaceuticals, Inc. in?
Mirum Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MIRM's market cap?
Mirum Pharmaceuticals, Inc. has a market capitalization of $3.84 billion, making it a mid-cap company.
Does MIRM pay dividends?
No, Mirum Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
ADMA
ADMA Biologics, Inc.
$19.58
Mkt Cap: $4.7B
BLTE
Belite Bio, Inc
$156.00
Mkt Cap: $5.4B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
LGND
Ligand Pharmaceuticals Incorporated
$200.33
Mkt Cap: $3.9B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
TLX
Telix Pharmaceuticals Limited
$7.80
Mkt Cap: $2.6B
TVTX
Travere Therapeutics, Inc.
$34.51
Mkt Cap: $3.1B
Explore stocks similar to MIRM for comparison